IP Library Patent Application 18241355
Patent Application
App. No. 18/241,355

METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/241,355
Abstract

The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.

Claims (20)

1 . A method of treating one or more symptoms of Irritable Bowel Syndrome (IBS) in a subject in need thereof, the method comprising:

orally administering to the subject a dosage form comprising 550 mg of rifaximin three times a day (TID) for 14 days,

wherein the symptoms are selected from cramping, diarrhea, constipation, lumpy stool, watery stool, frequent stool production, abdominal pain, abdominal discomfort, and/or bowel movement urgency, and wherein removing the subject from treatment after the 14 days results in from 1 to 24 weeks of adequate relief of the symptoms.

2 . The method of claim 1 , wherein the IBS is diarrhea-predominant IBS.

3 . The method of claim 1 , wherein the IBS is alternating-predominant IBS.

4 . (canceled)

5 . (canceled)

6 . The method of claim 1 , wherein the treating one or more IBS symptoms is a reduction from baseline symptoms.

7 . The method of claim 6 , wherein baseline symptoms are established prior to treatment.

8 . The method of claim 1 , wherein adequate relief of IBS symptoms comprise a ‘yes’ response from the subject when asked the question comprising “In the past 7 days, have you had adequate relief of your symptom of your IBS symptoms?”

9 . The method of claim 8 , wherein adequate relief of IBS symptoms comprises an affirmative response from the subject if asked whether they have had adequate relief of one or more symptoms of IBS.

10 - 19 . (canceled)

20 . The method of claim 1 , wherein the subject in need thereof is 65 years old or older.

21 . (canceled)

22 . The method of claim 1 , wherein the subject in need thereof is non-white.

23 - 25 . (canceled)

26 . The method of claim 1 , wherein treating is determined by an improvement in any one of: Weekly IBS Global Symptoms, IBS Daily Assessment of Symptoms, Daily IBS Global Symptoms, or Daily IBS Symptom of Abdominal Pain.

27 - 35 . (canceled)

36 . The method of claim 1 , wherein the subject in need thereof has a a diabetes history of longer than 20 years.

37 . The method of claim 1 , wherein removing the subject from treatment after the 14 days results in 4 weeks of adequate relief of the one or more IBS symptoms.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 16, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 065602/0371 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 16, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 065602/0380 →
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 16, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 065607/0979 →